(Q40401963)

20 September 2017

title

Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells (English)

1 reference

20 September 2017

main subject

protein ubiquitination

1 reference

Hiroyuki Michiue

1

1 reference

20 September 2017

Kazuhito Tomizawa

2

1 reference

20 September 2017

Masayuki Matsushita

3

1 reference

20 September 2017

Takashi Tamiya

4

1 reference

20 September 2017

Yun-Fei Lu

5

1 reference

20 September 2017

Tomotsugu Ichikawa

6

1 reference

20 September 2017

Isao Date

7

1 reference

20 September 2017

Hideki Matsui

8

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

579

1 reference

20 September 2017

issue

18

1 reference

20 September 2017

page(s)

3965-3969

1 reference

Protein transduction: unrestricted delivery into all cells?

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Protein transduction technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Transduction peptides: from technology to physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Gene therapy -- promises, problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Regulators split on gene therapy as patient shows signs of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.021

10.1016/J.FEBSLET.2005.06.021

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference